Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 7/20 | 0.52 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 3/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | XPNPEP1 | Q9NQW7 | 2/20 | 0.37 |
| ▸ | LAP3 | P28838 | 4/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9515708 | 1.00 | ANPEP (0.52) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| Hydrochloric Acid SCHEMBL9515723 | 1.00 | ANPEP (0.52) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| SCHEMBL11467290 | 0.98 | ANPEP (0.53) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| Hydrochloric Acid SCHEMBL9514577 | 0.82 | SLC7A5 (0.54) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| Hydrochloric Acid SCHEMBL9514582 | 0.82 | SLC7A5 (0.54) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| Hydrochloric Acid SCHEMBL9370266 | 0.82 | SLC7A5 (0.54) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| Hydrochloric Acid SCHEMBL737245 | 0.82 | SLC7A5 (0.54) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| SCHEMBL8357046 | 0.80 | ANPEP (0.38) | ANPEPDNPEPSLC7A5PEPDXPNPEP1 | |
| SCHEMBL13481584 | 0.79 | ANPEP (0.53) | ANPEPDNPEPSLC7A5PEPDSLC1A3 | |
| SCHEMBL762515 | 0.79 | SLC7A5 (0.56) | ANPEPDNPEPSLC7A5SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3523294-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Blade Therapeutics, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9139557-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-22 | — | — | US | disclosed |
| EP-2439205-B1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-20130245003-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2013-09-19 | — | — | US | disclosed |
| US-7728012-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-2121653-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008080969-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| EP-0266950-B1 | Nor-statine and nor-cyclostatine polypeptides | PFIZER (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | ANPEP 696/4885DNPEP 181/4885SLC7A5 4092/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | ANPEP 696/4885DNPEP 181/4885SLC7A5 4092/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | ANPEP 1311/4885DNPEP 615/4885SLC7A5 3707/4885 |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | ANPEP 743/4885DNPEP 162/4885SLC7A5 2703/4885 |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | ANPEP 743/4885DNPEP 162/4885SLC7A5 2703/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | ANPEP 696/4885DNPEP 181/4885SLC7A5 4092/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | ANPEP 696/4885DNPEP 181/4885SLC7A5 4092/4885 |
| US-20130245003-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAMK2A, CAPN2, CAPN1 | ANPEP 743/4885DNPEP 162/4885SLC7A5 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.